nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—Gefitinib—Erlotinib—kidney cancer	0.471	1	CrCrCtD
Iloperidone—CYP3A7—Temsirolimus—kidney cancer	0.035	0.0984	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.035	0.0984	CbGbCtD
Iloperidone—CYP3A5—Temsirolimus—kidney cancer	0.0263	0.0738	CbGbCtD
Iloperidone—HTR2C—Sorafenib—kidney cancer	0.0164	0.046	CbGbCtD
Iloperidone—CYP2D6—Temsirolimus—kidney cancer	0.0161	0.0453	CbGbCtD
Iloperidone—CYP3A4—Everolimus—kidney cancer	0.0152	0.0426	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.012	0.0338	CbGbCtD
Iloperidone—CYP3A7—Paclitaxel—kidney cancer	0.012	0.0338	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.0107	0.03	CbGbCtD
Iloperidone—CYP3A7—Sorafenib—kidney cancer	0.0107	0.03	CbGbCtD
Iloperidone—CYP3A7—Vincristine—kidney cancer	0.0104	0.0291	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.0104	0.0291	CbGbCtD
Iloperidone—CYP1A2—Pazopanib—kidney cancer	0.0103	0.0289	CbGbCtD
Iloperidone—CYP3A4—Temsirolimus—kidney cancer	0.0102	0.0288	CbGbCtD
Iloperidone—CYP3A5—Erlotinib—kidney cancer	0.00985	0.0277	CbGbCtD
Iloperidone—CYP3A5—Paclitaxel—kidney cancer	0.00902	0.0253	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.00865	0.0243	CbGbCtD
Iloperidone—CYP3A7—Sunitinib—kidney cancer	0.00865	0.0243	CbGbCtD
Iloperidone—CYP2D6—Pazopanib—kidney cancer	0.00847	0.0238	CbGbCtD
Iloperidone—CYP3A5—Sorafenib—kidney cancer	0.00801	0.0225	CbGbCtD
Iloperidone—CYP3A5—Vincristine—kidney cancer	0.00778	0.0218	CbGbCtD
Iloperidone—CYP1A2—Erlotinib—kidney cancer	0.00733	0.0206	CbGbCtD
Iloperidone—CYP3A5—Sunitinib—kidney cancer	0.00649	0.0182	CbGbCtD
Iloperidone—CYP2D6—Erlotinib—kidney cancer	0.00604	0.017	CbGbCtD
Iloperidone—CYP1A2—Sorafenib—kidney cancer	0.00596	0.0167	CbGbCtD
Iloperidone—CYP3A4—Pazopanib—kidney cancer	0.00538	0.0151	CbGbCtD
Iloperidone—CYP2D6—Sorafenib—kidney cancer	0.00491	0.0138	CbGbCtD
Iloperidone—CYP2D6—Vinblastine—kidney cancer	0.00485	0.0136	CbGbCtD
Iloperidone—CYP3A4—Erlotinib—kidney cancer	0.00384	0.0108	CbGbCtD
Iloperidone—CYP3A4—Paclitaxel—kidney cancer	0.00352	0.00988	CbGbCtD
Iloperidone—CYP3A4—Sorafenib—kidney cancer	0.00312	0.00877	CbGbCtD
Iloperidone—CYP3A4—Vinblastine—kidney cancer	0.00308	0.00866	CbGbCtD
Iloperidone—CYP3A4—Vincristine—kidney cancer	0.00303	0.00852	CbGbCtD
Iloperidone—CYP2D6—Doxorubicin—kidney cancer	0.00298	0.00837	CbGbCtD
Iloperidone—CYP3A4—Sunitinib—kidney cancer	0.00253	0.00711	CbGbCtD
Iloperidone—CYP3A4—Doxorubicin—kidney cancer	0.0019	0.00532	CbGbCtD
Iloperidone—CYP1A2—urine—kidney cancer	0.00109	0.074	CbGeAlD
Iloperidone—CYP2E1—urine—kidney cancer	0.000985	0.0666	CbGeAlD
Iloperidone—HTR2A—urine—kidney cancer	0.000856	0.0579	CbGeAlD
Iloperidone—CYP3A4—urine—kidney cancer	0.000792	0.0536	CbGeAlD
Iloperidone—CYP2D6—urine—kidney cancer	0.00078	0.0527	CbGeAlD
Iloperidone—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.000687	0.0464	CbGeAlD
Iloperidone—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.000588	0.0397	CbGeAlD
Iloperidone—SIGMAR1—nephron tubule—kidney cancer	0.000432	0.0292	CbGeAlD
Iloperidone—HTR1D—kidney—kidney cancer	0.000408	0.0276	CbGeAlD
Iloperidone—SIGMAR1—cortex of kidney—kidney cancer	0.00037	0.025	CbGeAlD
Iloperidone—SIGMAR1—cardiac atrium—kidney cancer	0.000352	0.0238	CbGeAlD
Iloperidone—HTR1A—renal system—kidney cancer	0.000351	0.0238	CbGeAlD
Iloperidone—ADRA2C—nephron tubule—kidney cancer	0.00034	0.023	CbGeAlD
Iloperidone—HTR7—renal system—kidney cancer	0.000336	0.0227	CbGeAlD
Iloperidone—HTR7—kidney—kidney cancer	0.000325	0.0219	CbGeAlD
Iloperidone—ADRA1A—renal system—kidney cancer	0.000324	0.0219	CbGeAlD
Iloperidone—ADRA2C—renal system—kidney cancer	0.000309	0.0209	CbGeAlD
Iloperidone—HTR7—gonad—kidney cancer	0.000301	0.0204	CbGeAlD
Iloperidone—ADRA2C—kidney—kidney cancer	0.000298	0.0202	CbGeAlD
Iloperidone—ADRA2C—cortex of kidney—kidney cancer	0.000291	0.0196	CbGeAlD
Iloperidone—CYP3A5—nephron tubule—kidney cancer	0.000284	0.0192	CbGeAlD
Iloperidone—ADRA2C—cardiac atrium—kidney cancer	0.000276	0.0187	CbGeAlD
Iloperidone—CYP1A2—renal system—kidney cancer	0.000268	0.0181	CbGeAlD
Iloperidone—CYP2E1—nephron tubule—kidney cancer	0.000265	0.0179	CbGeAlD
Iloperidone—CYP3A5—renal system—kidney cancer	0.000258	0.0175	CbGeAlD
Iloperidone—CYP3A5—kidney—kidney cancer	0.00025	0.0169	CbGeAlD
Iloperidone—CYP3A5—cortex of kidney—kidney cancer	0.000243	0.0164	CbGeAlD
Iloperidone—CYP2E1—renal system—kidney cancer	0.000241	0.0163	CbGeAlD
Iloperidone—CYP2E1—kidney—kidney cancer	0.000233	0.0157	CbGeAlD
Iloperidone—ADRA2A—cortex of kidney—kidney cancer	0.000232	0.0157	CbGeAlD
Iloperidone—CYP2E1—cortex of kidney—kidney cancer	0.000227	0.0153	CbGeAlD
Iloperidone—ADRA2A—gonad—kidney cancer	0.000221	0.0149	CbGeAlD
Iloperidone—ADRA2A—cardiac atrium—kidney cancer	0.000221	0.0149	CbGeAlD
Iloperidone—HTR2A—renal system—kidney cancer	0.000209	0.0142	CbGeAlD
Iloperidone—HTR2A—kidney—kidney cancer	0.000202	0.0137	CbGeAlD
Iloperidone—Gefitinib—CYP1A1—kidney cancer	0.000194	0.431	CrCbGaD
Iloperidone—CYP3A4—renal system—kidney cancer	0.000194	0.0131	CbGeAlD
Iloperidone—CYP2D6—renal system—kidney cancer	0.000191	0.0129	CbGeAlD
Iloperidone—HTR2A—gonad—kidney cancer	0.000188	0.0127	CbGeAlD
Iloperidone—CYP3A4—kidney—kidney cancer	0.000187	0.0127	CbGeAlD
Iloperidone—CYP2D6—kidney—kidney cancer	0.000184	0.0125	CbGeAlD
Iloperidone—Risperidone—ABCB1—kidney cancer	0.000153	0.339	CrCbGaD
Iloperidone—Dermatitis—Pazopanib—kidney cancer	0.000113	0.000864	CcSEcCtD
Iloperidone—Agitation—Vincristine—kidney cancer	0.000113	0.000861	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000112	0.000856	CcSEcCtD
Iloperidone—Oedema—Dactinomycin—kidney cancer	0.000112	0.000856	CcSEcCtD
Iloperidone—Body temperature increased—Everolimus—kidney cancer	0.000112	0.000856	CcSEcCtD
Iloperidone—Fluid retention—Doxorubicin—kidney cancer	0.000112	0.000855	CcSEcCtD
Iloperidone—Infection—Dactinomycin—kidney cancer	0.000112	0.00085	CcSEcCtD
Iloperidone—Urinary tract disorder—Paclitaxel—kidney cancer	0.000111	0.000844	CcSEcCtD
Iloperidone—Vertigo—Vincristine—kidney cancer	0.000111	0.000842	CcSEcCtD
Iloperidone—Abdominal discomfort—Capecitabine—kidney cancer	0.00011	0.00084	CcSEcCtD
Iloperidone—Connective tissue disorder—Paclitaxel—kidney cancer	0.00011	0.00084	CcSEcCtD
Iloperidone—Leukopenia—Vincristine—kidney cancer	0.00011	0.000839	CcSEcCtD
Iloperidone—Urethral disorder—Paclitaxel—kidney cancer	0.00011	0.000838	CcSEcCtD
Iloperidone—Dyspnoea—Sorafenib—kidney cancer	0.00011	0.000838	CcSEcCtD
Iloperidone—Dry eye—Doxorubicin—kidney cancer	0.000109	0.000832	CcSEcCtD
Iloperidone—Body temperature increased—Erlotinib—kidney cancer	0.000108	0.000826	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000108	0.000824	CcSEcCtD
Iloperidone—Anaemia—Gemcitabine—kidney cancer	0.000108	0.000822	CcSEcCtD
Iloperidone—Dysuria—Capecitabine—kidney cancer	0.000108	0.00082	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Capecitabine—kidney cancer	0.000107	0.000815	CcSEcCtD
Iloperidone—Nausea—Pazopanib—kidney cancer	0.000107	0.000814	CcSEcCtD
Iloperidone—Mouth ulceration—Doxorubicin—kidney cancer	0.000107	0.000814	CcSEcCtD
Iloperidone—Paraesthesia—Sunitinib—kidney cancer	0.000107	0.000812	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000106	0.000811	CcSEcCtD
Iloperidone—Fatigue—Sorafenib—kidney cancer	0.000106	0.00081	CcSEcCtD
Iloperidone—Dyspnoea—Sunitinib—kidney cancer	0.000106	0.000806	CcSEcCtD
Iloperidone—Eye disorder—Paclitaxel—kidney cancer	0.000105	0.000799	CcSEcCtD
Iloperidone—Myalgia—Vincristine—kidney cancer	0.000105	0.000798	CcSEcCtD
Iloperidone—Weight increased—Capecitabine—kidney cancer	0.000105	0.000798	CcSEcCtD
Iloperidone—Tinnitus—Paclitaxel—kidney cancer	0.000105	0.000797	CcSEcCtD
Iloperidone—Leukopenia—Gemcitabine—kidney cancer	0.000104	0.000796	CcSEcCtD
Iloperidone—Cardiac disorder—Paclitaxel—kidney cancer	0.000104	0.000793	CcSEcCtD
Iloperidone—Weight decreased—Capecitabine—kidney cancer	0.000104	0.000793	CcSEcCtD
Iloperidone—Gefitinib—ABCB1—kidney cancer	0.000103	0.229	CrCbGaD
Iloperidone—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000102	0.000781	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000102	0.00078	CcSEcCtD
Iloperidone—Asthenia—Vinblastine—kidney cancer	0.000102	0.00078	CcSEcCtD
Iloperidone—Fatigue—Sunitinib—kidney cancer	0.000102	0.00078	CcSEcCtD
Iloperidone—Asthenia—Everolimus—kidney cancer	0.000102	0.000777	CcSEcCtD
Iloperidone—Angiopathy—Paclitaxel—kidney cancer	0.000102	0.000776	CcSEcCtD
Iloperidone—Mediastinal disorder—Paclitaxel—kidney cancer	0.000101	0.000771	CcSEcCtD
Iloperidone—Oedema—Vincristine—kidney cancer	0.0001	0.000765	CcSEcCtD
Iloperidone—Arrhythmia—Paclitaxel—kidney cancer	0.0001	0.000764	CcSEcCtD
Iloperidone—Stomatitis—Capecitabine—kidney cancer	0.0001	0.000762	CcSEcCtD
Iloperidone—Infection—Vincristine—kidney cancer	9.97e-05	0.00076	CcSEcCtD
Iloperidone—Conjunctivitis—Capecitabine—kidney cancer	9.97e-05	0.00076	CcSEcCtD
Iloperidone—Myalgia—Gemcitabine—kidney cancer	9.93e-05	0.000757	CcSEcCtD
Iloperidone—Arthralgia—Gemcitabine—kidney cancer	9.93e-05	0.000757	CcSEcCtD
Iloperidone—Nervous system disorder—Vincristine—kidney cancer	9.84e-05	0.00075	CcSEcCtD
Iloperidone—Asthenia—Erlotinib—kidney cancer	9.84e-05	0.000749	CcSEcCtD
Iloperidone—Mental disorder—Paclitaxel—kidney cancer	9.83e-05	0.000749	CcSEcCtD
Iloperidone—Malnutrition—Paclitaxel—kidney cancer	9.77e-05	0.000744	CcSEcCtD
Iloperidone—Diarrhoea—Vinblastine—kidney cancer	9.76e-05	0.000743	CcSEcCtD
Iloperidone—Body temperature increased—Sorafenib—kidney cancer	9.75e-05	0.000743	CcSEcCtD
Iloperidone—Diarrhoea—Everolimus—kidney cancer	9.72e-05	0.000741	CcSEcCtD
Iloperidone—Hepatobiliary disease—Capecitabine—kidney cancer	9.7e-05	0.000739	CcSEcCtD
Iloperidone—Fatigue—Dactinomycin—kidney cancer	9.69e-05	0.000738	CcSEcCtD
Iloperidone—Epistaxis—Capecitabine—kidney cancer	9.68e-05	0.000737	CcSEcCtD
Iloperidone—Oedema—Gemcitabine—kidney cancer	9.52e-05	0.000725	CcSEcCtD
Iloperidone—Infection—Gemcitabine—kidney cancer	9.46e-05	0.000721	CcSEcCtD
Iloperidone—Dizziness—Vinblastine—kidney cancer	9.43e-05	0.000719	CcSEcCtD
Iloperidone—Dizziness—Everolimus—kidney cancer	9.4e-05	0.000716	CcSEcCtD
Iloperidone—Muscle spasms—Paclitaxel—kidney cancer	9.39e-05	0.000716	CcSEcCtD
Iloperidone—Body temperature increased—Sunitinib—kidney cancer	9.38e-05	0.000715	CcSEcCtD
Iloperidone—Diarrhoea—Erlotinib—kidney cancer	9.38e-05	0.000715	CcSEcCtD
Iloperidone—Hypotension—Vincristine—kidney cancer	9.38e-05	0.000715	CcSEcCtD
Iloperidone—Nervous system disorder—Gemcitabine—kidney cancer	9.34e-05	0.000711	CcSEcCtD
Iloperidone—Renal failure acute—Doxorubicin—kidney cancer	9.29e-05	0.000708	CcSEcCtD
Iloperidone—Feeling abnormal—Dactinomycin—kidney cancer	9.26e-05	0.000705	CcSEcCtD
Iloperidone—Vision blurred—Paclitaxel—kidney cancer	9.21e-05	0.000701	CcSEcCtD
Iloperidone—Tremor—Paclitaxel—kidney cancer	9.15e-05	0.000697	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Vincristine—kidney cancer	9.15e-05	0.000697	CcSEcCtD
Iloperidone—Increased appetite—Doxorubicin—kidney cancer	9.13e-05	0.000696	CcSEcCtD
Iloperidone—Urinary tract disorder—Capecitabine—kidney cancer	9.1e-05	0.000693	CcSEcCtD
Iloperidone—Dizziness—Erlotinib—kidney cancer	9.07e-05	0.000691	CcSEcCtD
Iloperidone—Connective tissue disorder—Capecitabine—kidney cancer	9.05e-05	0.000689	CcSEcCtD
Iloperidone—Anaemia—Paclitaxel—kidney cancer	9.03e-05	0.000688	CcSEcCtD
Iloperidone—Urethral disorder—Capecitabine—kidney cancer	9.03e-05	0.000688	CcSEcCtD
Iloperidone—Paraesthesia—Vincristine—kidney cancer	9.01e-05	0.000687	CcSEcCtD
Iloperidone—Agitation—Paclitaxel—kidney cancer	8.98e-05	0.000684	CcSEcCtD
Iloperidone—Rash—Everolimus—kidney cancer	8.96e-05	0.000683	CcSEcCtD
Iloperidone—Dermatitis—Everolimus—kidney cancer	8.95e-05	0.000682	CcSEcCtD
Iloperidone—Hypotension—Gemcitabine—kidney cancer	8.9e-05	0.000678	CcSEcCtD
Iloperidone—Body temperature increased—Dactinomycin—kidney cancer	8.88e-05	0.000677	CcSEcCtD
Iloperidone—Asthenia—Sorafenib—kidney cancer	8.85e-05	0.000674	CcSEcCtD
Iloperidone—Cardiac failure—Doxorubicin—kidney cancer	8.79e-05	0.00067	CcSEcCtD
Iloperidone—Vertigo—Paclitaxel—kidney cancer	8.78e-05	0.000669	CcSEcCtD
Iloperidone—Lethargy—Doxorubicin—kidney cancer	8.76e-05	0.000667	CcSEcCtD
Iloperidone—Leukopenia—Paclitaxel—kidney cancer	8.74e-05	0.000666	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Gemcitabine—kidney cancer	8.68e-05	0.000661	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Vincristine—kidney cancer	8.67e-05	0.00066	CcSEcCtD
Iloperidone—Fatigue—Vincristine—kidney cancer	8.65e-05	0.000659	CcSEcCtD
Iloperidone—Rash—Erlotinib—kidney cancer	8.64e-05	0.000659	CcSEcCtD
Iloperidone—Dermatitis—Erlotinib—kidney cancer	8.64e-05	0.000658	CcSEcCtD
Iloperidone—Palpitations—Paclitaxel—kidney cancer	8.63e-05	0.000658	CcSEcCtD
Iloperidone—Eye disorder—Capecitabine—kidney cancer	8.61e-05	0.000656	CcSEcCtD
Iloperidone—Tinnitus—Capecitabine—kidney cancer	8.59e-05	0.000654	CcSEcCtD
Iloperidone—Paraesthesia—Gemcitabine—kidney cancer	8.55e-05	0.000651	CcSEcCtD
Iloperidone—Cardiac disorder—Capecitabine—kidney cancer	8.55e-05	0.000651	CcSEcCtD
Iloperidone—Asthenia—Sunitinib—kidney cancer	8.52e-05	0.000649	CcSEcCtD
Iloperidone—Dyspnoea—Gemcitabine—kidney cancer	8.49e-05	0.000647	CcSEcCtD
Iloperidone—Nausea—Vinblastine—kidney cancer	8.47e-05	0.000645	CcSEcCtD
Iloperidone—Somnolence—Gemcitabine—kidney cancer	8.47e-05	0.000645	CcSEcCtD
Iloperidone—Affect lability—Doxorubicin—kidney cancer	8.45e-05	0.000643	CcSEcCtD
Iloperidone—Nausea—Everolimus—kidney cancer	8.44e-05	0.000643	CcSEcCtD
Iloperidone—Diarrhoea—Sorafenib—kidney cancer	8.44e-05	0.000643	CcSEcCtD
Iloperidone—Angiopathy—Capecitabine—kidney cancer	8.36e-05	0.000637	CcSEcCtD
Iloperidone—Myalgia—Paclitaxel—kidney cancer	8.32e-05	0.000634	CcSEcCtD
Iloperidone—Arthralgia—Paclitaxel—kidney cancer	8.32e-05	0.000634	CcSEcCtD
Iloperidone—Mediastinal disorder—Capecitabine—kidney cancer	8.3e-05	0.000632	CcSEcCtD
Iloperidone—Arrhythmia—Capecitabine—kidney cancer	8.23e-05	0.000627	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.22e-05	0.000626	CcSEcCtD
Iloperidone—Fatigue—Gemcitabine—kidney cancer	8.21e-05	0.000625	CcSEcCtD
Iloperidone—Dizziness—Sorafenib—kidney cancer	8.16e-05	0.000621	CcSEcCtD
Iloperidone—Nausea—Erlotinib—kidney cancer	8.14e-05	0.00062	CcSEcCtD
Iloperidone—Dry mouth—Paclitaxel—kidney cancer	8.13e-05	0.00062	CcSEcCtD
Iloperidone—Mood swings—Doxorubicin—kidney cancer	8.13e-05	0.000619	CcSEcCtD
Iloperidone—Diarrhoea—Sunitinib—kidney cancer	8.12e-05	0.000619	CcSEcCtD
Iloperidone—Mental disorder—Capecitabine—kidney cancer	8.07e-05	0.000615	CcSEcCtD
Iloperidone—Asthenia—Dactinomycin—kidney cancer	8.06e-05	0.000614	CcSEcCtD
Iloperidone—Confusional state—Paclitaxel—kidney cancer	8.04e-05	0.000612	CcSEcCtD
Iloperidone—Malnutrition—Capecitabine—kidney cancer	8.02e-05	0.000611	CcSEcCtD
Iloperidone—Dehydration—Doxorubicin—kidney cancer	7.98e-05	0.000608	CcSEcCtD
Iloperidone—Oedema—Paclitaxel—kidney cancer	7.97e-05	0.000607	CcSEcCtD
Iloperidone—Body temperature increased—Vincristine—kidney cancer	7.94e-05	0.000605	CcSEcCtD
Iloperidone—Infection—Paclitaxel—kidney cancer	7.92e-05	0.000603	CcSEcCtD
Iloperidone—Dizziness—Sunitinib—kidney cancer	7.85e-05	0.000598	CcSEcCtD
Iloperidone—Feeling abnormal—Gemcitabine—kidney cancer	7.85e-05	0.000598	CcSEcCtD
Iloperidone—Orthostatic hypotension—Doxorubicin—kidney cancer	7.84e-05	0.000597	CcSEcCtD
Iloperidone—Nervous system disorder—Paclitaxel—kidney cancer	7.82e-05	0.000596	CcSEcCtD
Iloperidone—Hypokalaemia—Doxorubicin—kidney cancer	7.81e-05	0.000595	CcSEcCtD
Iloperidone—Tachycardia—Paclitaxel—kidney cancer	7.78e-05	0.000593	CcSEcCtD
Iloperidone—Rash—Sorafenib—kidney cancer	7.78e-05	0.000592	CcSEcCtD
Iloperidone—Dermatitis—Sorafenib—kidney cancer	7.77e-05	0.000592	CcSEcCtD
Iloperidone—Breast disorder—Doxorubicin—kidney cancer	7.75e-05	0.000591	CcSEcCtD
Iloperidone—Muscle spasms—Capecitabine—kidney cancer	7.71e-05	0.000587	CcSEcCtD
Iloperidone—Diarrhoea—Dactinomycin—kidney cancer	7.69e-05	0.000586	CcSEcCtD
Iloperidone—Nasopharyngitis—Doxorubicin—kidney cancer	7.67e-05	0.000585	CcSEcCtD
Iloperidone—Gastritis—Doxorubicin—kidney cancer	7.59e-05	0.000579	CcSEcCtD
Iloperidone—Vision blurred—Capecitabine—kidney cancer	7.56e-05	0.000576	CcSEcCtD
Iloperidone—Body temperature increased—Gemcitabine—kidney cancer	7.53e-05	0.000574	CcSEcCtD
Iloperidone—Tremor—Capecitabine—kidney cancer	7.51e-05	0.000572	CcSEcCtD
Iloperidone—Rash—Sunitinib—kidney cancer	7.48e-05	0.00057	CcSEcCtD
Iloperidone—Dermatitis—Sunitinib—kidney cancer	7.48e-05	0.00057	CcSEcCtD
Iloperidone—Hypotension—Paclitaxel—kidney cancer	7.45e-05	0.000568	CcSEcCtD
Iloperidone—Asthma—Doxorubicin—kidney cancer	7.42e-05	0.000565	CcSEcCtD
Iloperidone—Anaemia—Capecitabine—kidney cancer	7.41e-05	0.000565	CcSEcCtD
Iloperidone—Nausea—Sorafenib—kidney cancer	7.33e-05	0.000558	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.26e-05	0.000553	CcSEcCtD
Iloperidone—Vertigo—Capecitabine—kidney cancer	7.2e-05	0.000549	CcSEcCtD
Iloperidone—Asthenia—Vincristine—kidney cancer	7.2e-05	0.000549	CcSEcCtD
Iloperidone—Leukopenia—Capecitabine—kidney cancer	7.18e-05	0.000547	CcSEcCtD
Iloperidone—Paraesthesia—Paclitaxel—kidney cancer	7.16e-05	0.000545	CcSEcCtD
Iloperidone—Dyspnoea—Paclitaxel—kidney cancer	7.11e-05	0.000542	CcSEcCtD
Iloperidone—Somnolence—Paclitaxel—kidney cancer	7.09e-05	0.00054	CcSEcCtD
Iloperidone—Palpitations—Capecitabine—kidney cancer	7.08e-05	0.00054	CcSEcCtD
Iloperidone—Rash—Dactinomycin—kidney cancer	7.08e-05	0.00054	CcSEcCtD
Iloperidone—Nausea—Sunitinib—kidney cancer	7.05e-05	0.000537	CcSEcCtD
Iloperidone—Dysuria—Doxorubicin—kidney cancer	6.94e-05	0.000528	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Doxorubicin—kidney cancer	6.89e-05	0.000525	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Paclitaxel—kidney cancer	6.88e-05	0.000524	CcSEcCtD
Iloperidone—Fatigue—Paclitaxel—kidney cancer	6.87e-05	0.000524	CcSEcCtD
Iloperidone—Diarrhoea—Vincristine—kidney cancer	6.87e-05	0.000523	CcSEcCtD
Iloperidone—Pollakiuria—Doxorubicin—kidney cancer	6.85e-05	0.000522	CcSEcCtD
Iloperidone—Asthenia—Gemcitabine—kidney cancer	6.83e-05	0.000521	CcSEcCtD
Iloperidone—Myalgia—Capecitabine—kidney cancer	6.83e-05	0.00052	CcSEcCtD
Iloperidone—Arthralgia—Capecitabine—kidney cancer	6.83e-05	0.00052	CcSEcCtD
Iloperidone—Weight increased—Doxorubicin—kidney cancer	6.75e-05	0.000514	CcSEcCtD
Iloperidone—Weight decreased—Doxorubicin—kidney cancer	6.71e-05	0.000511	CcSEcCtD
Iloperidone—Dry mouth—Capecitabine—kidney cancer	6.68e-05	0.000509	CcSEcCtD
Iloperidone—Nausea—Dactinomycin—kidney cancer	6.67e-05	0.000508	CcSEcCtD
Iloperidone—Dizziness—Vincristine—kidney cancer	6.64e-05	0.000506	CcSEcCtD
Iloperidone—Confusional state—Capecitabine—kidney cancer	6.6e-05	0.000503	CcSEcCtD
Iloperidone—Feeling abnormal—Paclitaxel—kidney cancer	6.57e-05	0.000501	CcSEcCtD
Iloperidone—Oedema—Capecitabine—kidney cancer	6.54e-05	0.000498	CcSEcCtD
Iloperidone—Diarrhoea—Gemcitabine—kidney cancer	6.52e-05	0.000496	CcSEcCtD
Iloperidone—Infection—Capecitabine—kidney cancer	6.5e-05	0.000495	CcSEcCtD
Iloperidone—Stomatitis—Doxorubicin—kidney cancer	6.45e-05	0.000491	CcSEcCtD
Iloperidone—Conjunctivitis—Doxorubicin—kidney cancer	6.43e-05	0.00049	CcSEcCtD
Iloperidone—Nervous system disorder—Capecitabine—kidney cancer	6.42e-05	0.000489	CcSEcCtD
Iloperidone—Tachycardia—Capecitabine—kidney cancer	6.39e-05	0.000486	CcSEcCtD
Iloperidone—Rash—Vincristine—kidney cancer	6.33e-05	0.000482	CcSEcCtD
Iloperidone—Dermatitis—Vincristine—kidney cancer	6.32e-05	0.000482	CcSEcCtD
Iloperidone—Body temperature increased—Paclitaxel—kidney cancer	6.3e-05	0.00048	CcSEcCtD
Iloperidone—Hepatobiliary disease—Doxorubicin—kidney cancer	6.25e-05	0.000476	CcSEcCtD
Iloperidone—Epistaxis—Doxorubicin—kidney cancer	6.24e-05	0.000475	CcSEcCtD
Iloperidone—Hypotension—Capecitabine—kidney cancer	6.11e-05	0.000466	CcSEcCtD
Iloperidone—Rash—Gemcitabine—kidney cancer	6e-05	0.000457	CcSEcCtD
Iloperidone—Dermatitis—Gemcitabine—kidney cancer	6e-05	0.000457	CcSEcCtD
Iloperidone—Nausea—Vincristine—kidney cancer	5.96e-05	0.000454	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Capecitabine—kidney cancer	5.96e-05	0.000454	CcSEcCtD
Iloperidone—Paraesthesia—Capecitabine—kidney cancer	5.88e-05	0.000448	CcSEcCtD
Iloperidone—Urinary tract disorder—Doxorubicin—kidney cancer	5.86e-05	0.000447	CcSEcCtD
Iloperidone—Connective tissue disorder—Doxorubicin—kidney cancer	5.83e-05	0.000444	CcSEcCtD
Iloperidone—Dyspnoea—Capecitabine—kidney cancer	5.83e-05	0.000444	CcSEcCtD
Iloperidone—Urethral disorder—Doxorubicin—kidney cancer	5.82e-05	0.000443	CcSEcCtD
Iloperidone—Asthenia—Paclitaxel—kidney cancer	5.72e-05	0.000436	CcSEcCtD
Iloperidone—Nausea—Gemcitabine—kidney cancer	5.66e-05	0.000431	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Capecitabine—kidney cancer	5.65e-05	0.00043	CcSEcCtD
Iloperidone—Fatigue—Capecitabine—kidney cancer	5.64e-05	0.00043	CcSEcCtD
Iloperidone—Eye disorder—Doxorubicin—kidney cancer	5.55e-05	0.000423	CcSEcCtD
Iloperidone—Tinnitus—Doxorubicin—kidney cancer	5.54e-05	0.000422	CcSEcCtD
Iloperidone—Cardiac disorder—Doxorubicin—kidney cancer	5.51e-05	0.00042	CcSEcCtD
Iloperidone—Diarrhoea—Paclitaxel—kidney cancer	5.46e-05	0.000416	CcSEcCtD
Iloperidone—Feeling abnormal—Capecitabine—kidney cancer	5.39e-05	0.000411	CcSEcCtD
Iloperidone—Angiopathy—Doxorubicin—kidney cancer	5.39e-05	0.00041	CcSEcCtD
Iloperidone—Mediastinal disorder—Doxorubicin—kidney cancer	5.35e-05	0.000408	CcSEcCtD
Iloperidone—Arrhythmia—Doxorubicin—kidney cancer	5.3e-05	0.000404	CcSEcCtD
Iloperidone—Dizziness—Paclitaxel—kidney cancer	5.27e-05	0.000402	CcSEcCtD
Iloperidone—Mental disorder—Doxorubicin—kidney cancer	5.2e-05	0.000396	CcSEcCtD
Iloperidone—Body temperature increased—Capecitabine—kidney cancer	5.17e-05	0.000394	CcSEcCtD
Iloperidone—Malnutrition—Doxorubicin—kidney cancer	5.17e-05	0.000394	CcSEcCtD
Iloperidone—Rash—Paclitaxel—kidney cancer	5.03e-05	0.000383	CcSEcCtD
Iloperidone—Dermatitis—Paclitaxel—kidney cancer	5.02e-05	0.000383	CcSEcCtD
Iloperidone—Muscle spasms—Doxorubicin—kidney cancer	4.97e-05	0.000379	CcSEcCtD
Iloperidone—Vision blurred—Doxorubicin—kidney cancer	4.87e-05	0.000371	CcSEcCtD
Iloperidone—Anaemia—Doxorubicin—kidney cancer	4.78e-05	0.000364	CcSEcCtD
Iloperidone—Agitation—Doxorubicin—kidney cancer	4.75e-05	0.000362	CcSEcCtD
Iloperidone—Nausea—Paclitaxel—kidney cancer	4.74e-05	0.000361	CcSEcCtD
Iloperidone—Asthenia—Capecitabine—kidney cancer	4.69e-05	0.000358	CcSEcCtD
Iloperidone—Vertigo—Doxorubicin—kidney cancer	4.64e-05	0.000354	CcSEcCtD
Iloperidone—Leukopenia—Doxorubicin—kidney cancer	4.63e-05	0.000352	CcSEcCtD
Iloperidone—Palpitations—Doxorubicin—kidney cancer	4.57e-05	0.000348	CcSEcCtD
Iloperidone—Diarrhoea—Capecitabine—kidney cancer	4.48e-05	0.000341	CcSEcCtD
Iloperidone—Myalgia—Doxorubicin—kidney cancer	4.4e-05	0.000335	CcSEcCtD
Iloperidone—Arthralgia—Doxorubicin—kidney cancer	4.4e-05	0.000335	CcSEcCtD
Iloperidone—Dizziness—Capecitabine—kidney cancer	4.33e-05	0.00033	CcSEcCtD
Iloperidone—Dry mouth—Doxorubicin—kidney cancer	4.3e-05	0.000328	CcSEcCtD
Iloperidone—Confusional state—Doxorubicin—kidney cancer	4.25e-05	0.000324	CcSEcCtD
Iloperidone—Oedema—Doxorubicin—kidney cancer	4.22e-05	0.000321	CcSEcCtD
Iloperidone—Infection—Doxorubicin—kidney cancer	4.19e-05	0.000319	CcSEcCtD
Iloperidone—Nervous system disorder—Doxorubicin—kidney cancer	4.14e-05	0.000315	CcSEcCtD
Iloperidone—Rash—Capecitabine—kidney cancer	4.13e-05	0.000314	CcSEcCtD
Iloperidone—Dermatitis—Capecitabine—kidney cancer	4.12e-05	0.000314	CcSEcCtD
Iloperidone—Tachycardia—Doxorubicin—kidney cancer	4.12e-05	0.000314	CcSEcCtD
Iloperidone—Hypotension—Doxorubicin—kidney cancer	3.94e-05	0.0003	CcSEcCtD
Iloperidone—Nausea—Capecitabine—kidney cancer	3.89e-05	0.000296	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.84e-05	0.000293	CcSEcCtD
Iloperidone—Paraesthesia—Doxorubicin—kidney cancer	3.79e-05	0.000289	CcSEcCtD
Iloperidone—Dyspnoea—Doxorubicin—kidney cancer	3.76e-05	0.000286	CcSEcCtD
Iloperidone—Somnolence—Doxorubicin—kidney cancer	3.75e-05	0.000286	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.64e-05	0.000277	CcSEcCtD
Iloperidone—Fatigue—Doxorubicin—kidney cancer	3.64e-05	0.000277	CcSEcCtD
Iloperidone—Feeling abnormal—Doxorubicin—kidney cancer	3.48e-05	0.000265	CcSEcCtD
Iloperidone—Body temperature increased—Doxorubicin—kidney cancer	3.33e-05	0.000254	CcSEcCtD
Iloperidone—Asthenia—Doxorubicin—kidney cancer	3.03e-05	0.000231	CcSEcCtD
Iloperidone—Diarrhoea—Doxorubicin—kidney cancer	2.89e-05	0.00022	CcSEcCtD
Iloperidone—Dizziness—Doxorubicin—kidney cancer	2.79e-05	0.000212	CcSEcCtD
Iloperidone—Rash—Doxorubicin—kidney cancer	2.66e-05	0.000203	CcSEcCtD
Iloperidone—Dermatitis—Doxorubicin—kidney cancer	2.66e-05	0.000202	CcSEcCtD
Iloperidone—Nausea—Doxorubicin—kidney cancer	2.51e-05	0.000191	CcSEcCtD
Iloperidone—ADRA1A—Signaling Pathways—BRAF—kidney cancer	2.3e-06	8.59e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTGS1—kidney cancer	2.3e-06	8.57e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	2.29e-06	8.54e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—CTNNB1—kidney cancer	2.29e-06	8.54e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PTEN—kidney cancer	2.29e-06	8.53e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	2.28e-06	8.51e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—CCND1—kidney cancer	2.28e-06	8.51e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	2.28e-06	8.5e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—APC—kidney cancer	2.28e-06	8.49e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KIT—kidney cancer	2.28e-06	8.49e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—MAPK1—kidney cancer	2.28e-06	8.49e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—JUN—kidney cancer	2.28e-06	8.49e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—RAF1—kidney cancer	2.27e-06	8.48e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.27e-06	8.45e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—RELA—kidney cancer	2.26e-06	8.44e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—RAF1—kidney cancer	2.26e-06	8.44e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—CTNNB1—kidney cancer	2.26e-06	8.42e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PSMD7—kidney cancer	2.25e-06	8.41e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—RELA—kidney cancer	2.25e-06	8.4e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—ERBB2—kidney cancer	2.25e-06	8.39e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—VEGFA—kidney cancer	2.24e-06	8.35e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—ERBB2—kidney cancer	2.24e-06	8.35e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.24e-06	8.34e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	2.23e-06	8.33e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—PTEN—kidney cancer	2.23e-06	8.32e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MTOR—kidney cancer	2.22e-06	8.28e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PTEN—kidney cancer	2.22e-06	8.28e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—PIK3CA—kidney cancer	2.22e-06	8.27e-05	CbGpPWpGaD
Iloperidone—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	2.22e-06	8.26e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MAPK3—kidney cancer	2.21e-06	8.26e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MAPK3—kidney cancer	2.21e-06	8.25e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MTOR—kidney cancer	2.21e-06	8.24e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—GSTP1—kidney cancer	2.2e-06	8.22e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—PTEN—kidney cancer	2.2e-06	8.21e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—RAF1—kidney cancer	2.2e-06	8.21e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MAPK3—kidney cancer	2.2e-06	8.2e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—RELA—kidney cancer	2.19e-06	8.17e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—KRAS—kidney cancer	2.19e-06	8.17e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	2.18e-06	8.13e-05	CbGpPWpGaD
Iloperidone—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	2.18e-06	8.13e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—ERBB2—kidney cancer	2.18e-06	8.12e-05	CbGpPWpGaD
Iloperidone—HRH1—GPCR downstream signaling—PIK3CA—kidney cancer	2.18e-06	8.11e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—POMC—kidney cancer	2.17e-06	8.08e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—KRAS—kidney cancer	2.15e-06	8.03e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MYC—kidney cancer	2.15e-06	8.03e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MYC—kidney cancer	2.15e-06	8.02e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—KRAS—kidney cancer	2.15e-06	8.02e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MTOR—kidney cancer	2.15e-06	8.01e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—BRAF—kidney cancer	2.14e-06	7.98e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MYC—kidney cancer	2.14e-06	7.97e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—BCHE—kidney cancer	2.14e-06	7.97e-05	CbGpPWpGaD
Iloperidone—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	2.13e-06	7.96e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MAPK3—kidney cancer	2.12e-06	7.9e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.11e-06	7.87e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	2.11e-06	7.87e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MAPK1—kidney cancer	2.11e-06	7.86e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MAPK1—kidney cancer	2.11e-06	7.85e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MAPK1—kidney cancer	2.09e-06	7.8e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—ABCB1—kidney cancer	2.09e-06	7.78e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	2.08e-06	7.77e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	2.08e-06	7.74e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	2.07e-06	7.73e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTGS2—kidney cancer	2.07e-06	7.71e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MYC—kidney cancer	2.06e-06	7.68e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL2—kidney cancer	2.04e-06	7.6e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.04e-06	7.6e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL2—kidney cancer	2.03e-06	7.57e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—GSTM1—kidney cancer	2.03e-06	7.55e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	2.02e-06	7.52e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—VEGFA—kidney cancer	2.02e-06	7.52e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MAPK1—kidney cancer	2.02e-06	7.51e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	2.01e-06	7.5e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—RAF1—kidney cancer	2e-06	7.45e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—KRAS—kidney cancer	1.99e-06	7.42e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—VEGFA—kidney cancer	1.99e-06	7.42e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—KRAS—kidney cancer	1.99e-06	7.41e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—RELA—kidney cancer	1.99e-06	7.41e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CCND1—kidney cancer	1.99e-06	7.41e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—JUN—kidney cancer	1.98e-06	7.4e-05	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	1.98e-06	7.4e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	1.98e-06	7.38e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CCND1—kidney cancer	1.98e-06	7.37e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—ERBB2—kidney cancer	1.98e-06	7.37e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	1.98e-06	7.37e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—KRAS—kidney cancer	1.98e-06	7.37e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—JUN—kidney cancer	1.97e-06	7.36e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL2—kidney cancer	1.97e-06	7.36e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	1.97e-06	7.34e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—RAF1—kidney cancer	1.96e-06	7.33e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—RAF1—kidney cancer	1.96e-06	7.31e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	1.96e-06	7.31e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	1.96e-06	7.3e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—RELA—kidney cancer	1.96e-06	7.29e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—RELA—kidney cancer	1.95e-06	7.28e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MTOR—kidney cancer	1.95e-06	7.27e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—ERBB2—kidney cancer	1.94e-06	7.25e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—ERBB2—kidney cancer	1.94e-06	7.23e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	1.94e-06	7.23e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—RAF1—kidney cancer	1.92e-06	7.17e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CCND1—kidney cancer	1.92e-06	7.17e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CYP1A1—kidney cancer	1.92e-06	7.16e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—JUN—kidney cancer	1.92e-06	7.16e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PTEN—kidney cancer	1.92e-06	7.15e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MTOR—kidney cancer	1.92e-06	7.15e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—RELA—kidney cancer	1.92e-06	7.14e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MTOR—kidney cancer	1.91e-06	7.14e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PTEN—kidney cancer	1.91e-06	7.12e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MAPK3—kidney cancer	1.91e-06	7.11e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	1.91e-06	7.1e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	1.9e-06	7.1e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—KRAS—kidney cancer	1.9e-06	7.1e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTGS2—kidney cancer	1.9e-06	7.08e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTGS2—kidney cancer	1.9e-06	7.07e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MAPK3—kidney cancer	1.88e-06	7.01e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MTOR—kidney cancer	1.88e-06	7e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PTEN—kidney cancer	1.86e-06	6.92e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MYC—kidney cancer	1.85e-06	6.91e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CDKN1B—kidney cancer	1.83e-06	6.82e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MYC—kidney cancer	1.83e-06	6.82e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—PIK3CA—kidney cancer	1.83e-06	6.82e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—PIK3CA—kidney cancer	1.83e-06	6.81e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	1.81e-06	6.77e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MAPK1—kidney cancer	1.81e-06	6.76e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTEN—kidney cancer	1.8e-06	6.73e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	1.8e-06	6.72e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	1.8e-06	6.71e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CDKN1B—kidney cancer	1.8e-06	6.7e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL2—kidney cancer	1.79e-06	6.68e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MAPK1—kidney cancer	1.79e-06	6.67e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—RAF1—kidney cancer	1.79e-06	6.67e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—RELA—kidney cancer	1.78e-06	6.64e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—kidney cancer	1.77e-06	6.6e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	1.77e-06	6.59e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—kidney cancer	1.77e-06	6.59e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	1.76e-06	6.57e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL2—kidney cancer	1.76e-06	6.57e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL2—kidney cancer	1.76e-06	6.56e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—kidney cancer	1.76e-06	6.55e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—PIK3CA—kidney cancer	1.75e-06	6.52e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCND1—kidney cancer	1.75e-06	6.51e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MTOR—kidney cancer	1.75e-06	6.51e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—JUN—kidney cancer	1.74e-06	6.49e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—VEGFA—kidney cancer	1.73e-06	6.46e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CTNNB1—kidney cancer	1.73e-06	6.45e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL2—kidney cancer	1.73e-06	6.43e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—VEGFA—kidney cancer	1.72e-06	6.43e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCND1—kidney cancer	1.72e-06	6.4e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—JUN—kidney cancer	1.71e-06	6.39e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCND1—kidney cancer	1.71e-06	6.39e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—KRAS—kidney cancer	1.71e-06	6.39e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—JUN—kidney cancer	1.71e-06	6.38e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	1.7e-06	6.34e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTP1—kidney cancer	1.7e-06	6.34e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CTNNB1—kidney cancer	1.7e-06	6.33e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—kidney cancer	1.69e-06	6.31e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—KRAS—kidney cancer	1.69e-06	6.3e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—POMC—kidney cancer	1.69e-06	6.3e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PTEN—kidney cancer	1.68e-06	6.28e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCND1—kidney cancer	1.68e-06	6.27e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—JUN—kidney cancer	1.68e-06	6.26e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	1.68e-06	6.25e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	1.67e-06	6.21e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PTEN—kidney cancer	1.66e-06	6.18e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTEN—kidney cancer	1.66e-06	6.18e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PTEN—kidney cancer	1.65e-06	6.17e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTEN—kidney cancer	1.65e-06	6.16e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MAPK3—kidney cancer	1.64e-06	6.11e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	1.64e-06	6.11e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MAPK3—kidney cancer	1.63e-06	6.08e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PTEN—kidney cancer	1.62e-06	6.05e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PIK3CA—kidney cancer	1.61e-06	6.01e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ABCB1—kidney cancer	1.61e-06	6e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL2—kidney cancer	1.6e-06	5.98e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MYC—kidney cancer	1.59e-06	5.95e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	1.59e-06	5.92e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MYC—kidney cancer	1.59e-06	5.92e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.58e-06	5.88e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—PIK3CA—kidney cancer	1.57e-06	5.87e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PIK3CA—kidney cancer	1.57e-06	5.84e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTM1—kidney cancer	1.56e-06	5.83e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCND1—kidney cancer	1.56e-06	5.83e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MAPK1—kidney cancer	1.56e-06	5.82e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—JUN—kidney cancer	1.56e-06	5.81e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—PIK3CA—kidney cancer	1.55e-06	5.79e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MAPK1—kidney cancer	1.55e-06	5.79e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	1.55e-06	5.77e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MYC—kidney cancer	1.54e-06	5.75e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—kidney cancer	1.52e-06	5.68e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—VEGFA—kidney cancer	1.52e-06	5.67e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	1.51e-06	5.63e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PTEN—kidney cancer	1.51e-06	5.62e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—kidney cancer	1.5e-06	5.6e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—VEGFA—kidney cancer	1.5e-06	5.58e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—VEGFA—kidney cancer	1.49e-06	5.57e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.48e-06	5.52e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—KRAS—kidney cancer	1.47e-06	5.49e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	1.47e-06	5.47e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—KRAS—kidney cancer	1.47e-06	5.47e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK3—kidney cancer	1.44e-06	5.37e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—POMC—kidney cancer	1.43e-06	5.34e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—KRAS—kidney cancer	1.43e-06	5.32e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK3—kidney cancer	1.42e-06	5.28e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK3—kidney cancer	1.41e-06	5.27e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MYC—kidney cancer	1.4e-06	5.22e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	1.39e-06	5.17e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MYC—kidney cancer	1.38e-06	5.14e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MYC—kidney cancer	1.37e-06	5.13e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK1—kidney cancer	1.37e-06	5.11e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	1.36e-06	5.08e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	1.35e-06	5.05e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MYC—kidney cancer	1.35e-06	5.03e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK1—kidney cancer	1.35e-06	5.03e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTGS2—kidney cancer	1.35e-06	5.03e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	1.35e-06	5.02e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK1—kidney cancer	1.34e-06	5.01e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	1.32e-06	4.92e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	1.31e-06	4.88e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—kidney cancer	1.31e-06	4.88e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—kidney cancer	1.3e-06	4.86e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—KRAS—kidney cancer	1.29e-06	4.82e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	1.29e-06	4.8e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—KRAS—kidney cancer	1.27e-06	4.75e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PIK3CA—kidney cancer	1.27e-06	4.74e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—KRAS—kidney cancer	1.27e-06	4.74e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—kidney cancer	1.27e-06	4.73e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MYC—kidney cancer	1.25e-06	4.67e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—KRAS—kidney cancer	1.25e-06	4.65e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	1.23e-06	4.57e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PIK3CA—kidney cancer	1.19e-06	4.43e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTEN—kidney cancer	1.18e-06	4.38e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	1.17e-06	4.36e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PIK3CA—kidney cancer	1.17e-06	4.36e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PIK3CA—kidney cancer	1.17e-06	4.35e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.17e-06	4.35e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KRAS—kidney cancer	1.16e-06	4.32e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—kidney cancer	1.15e-06	4.29e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	1.15e-06	4.27e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTGS2—kidney cancer	1.14e-06	4.26e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—kidney cancer	1.13e-06	4.22e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—kidney cancer	1.13e-06	4.21e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—kidney cancer	1.11e-06	4.13e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—POMC—kidney cancer	1.1e-06	4.12e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	1.06e-06	3.97e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—kidney cancer	1.03e-06	3.84e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTEN—kidney cancer	9.96e-07	3.71e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTGS2—kidney cancer	8.81e-07	3.29e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CA—kidney cancer	8.29e-07	3.09e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTEN—kidney cancer	7.68e-07	2.87e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CA—kidney cancer	7.02e-07	2.62e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CA—kidney cancer	5.42e-07	2.02e-05	CbGpPWpGaD
